elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q26769884-2A7FB923-5558-45A7-BCD8-E6157F565983
Q26769884-2A7FB923-5558-45A7-BCD8-E6157F565983
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26769884-2A7FB923-5558-45A7-BCD8-E6157F565983
Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential
P2860
Q26769884-2A7FB923-5558-45A7-BCD8-E6157F565983
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26769884-2A7FB923-5558-45A7-BCD8-E6157F565983
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
da8fe9ffe9e9f074810f60d20acb0d9a9f1f3f82
P2860
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer